tradingkey.logo
tradingkey.logo
Search

BioVie Inc

BIVI
Add to Watchlist
1.630USD
0.0000.00%
Close 09-22 16:00ET
12.29MMarket Cap
LossP/E TTM

About BioVie Inc Company

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

BioVie Inc Profile

Ticker SymbolBIVI
Company nameBioVie Inc
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)
Number of employees13
Security typeOrdinary Share
Fiscal year-endJan 14
Address680 W Nye Lane
CityCARSON CITY
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code89703
Phone17758883162
Websitehttps://www.bioviepharma.com/
Ticker SymbolBIVI
IPO dateJan 14, 2014
CEODo (Viet Cuong Viet)

Company Executives of BioVie Inc

Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
6.04K
+80.24%
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
6.04K
+80.24%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
3.44K
+72.65%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
3.44K
+72.65%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
--
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Mr. Michael Edward Sherman, J.D.
Mr. Michael Edward Sherman, J.D.
Independent Director
Independent Director
208.00
--
Mr. Sigmund (Sig) Rogich
Mr. Sigmund (Sig) Rogich
Independent Director
Independent Director
--
--
Mr. Viet Cuong Do
Mr. Viet Cuong Do
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
6.04K
+80.24%
Dr. Joseph M. Palumbo, M.D.
Dr. Joseph M. Palumbo, M.D.
Chief Medical Officer
Chief Medical Officer
6.04K
+80.24%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
3.44K
+72.65%
Ms. Joanne Wendy Kim, CPA
Ms. Joanne Wendy Kim, CPA
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
3.44K
+72.65%
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
--
Mr. James (Jim) Lang
Mr. James (Jim) Lang
Independent Chairman of the Board
Independent Chairman of the Board
690.00
--

FAQs

Who are the top five shareholders of BioVie Inc?

The top five shareholders of BioVie Inc are: Dr. Joseph M. Palumbo, M.D.

How many institutions hold shares of BioVie Inc (BIVI)?

As of 2026Q1, 125 institutions hold shares of BioVie Inc, with a combined market value of approximately 1.18M, accounting for 15.63% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -357412.00.
tradingkey.logo
Risk Warning: Our Website and Mobile App provides only general information on certain investment products. Finsights does not provide, and the provision of such information must not be construed as Finsights providing, financial advice or recommendation for any investment product.
Investment products are subject to significant investment risks, including the possible loss of the principal amount invested and may not be suitable for everyone. Past performance of investment products is not indicative of their future performance.
Finsights may allow third party advertisers or affiliates to place or deliver advertisements on our Website or Mobile App or any part thereof and may be compensated by them based on your interaction with the advertisements.
© Copyright: FINSIGHTS MEDIA PTE. LTD. All Rights Reserved.